Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

E. Jensen-Jarolim; J. Singer

doi:10.1111/j.1365-2222.2011.03764.x

Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

E. Jensen-Jarolim^*, J. Singer

^*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Journal article

9 Citations (Scopus)

Original language	English
Pages (from-to)	1337-1340
Number of pages	4
Journal	Clinical and Experimental Allergy
Volume	41
Issue number	10
DOIs	https://doi.org/10.1111/j.1365-2222.2011.03764.x
Publication status	Published - Oct 2011
Externally published	Yes

Keywords

Animals
Antibodies, Monoclonal, Murine-Derived/adverse effects
Basophils/immunology
Carcinoma/therapy
Female
Folate Receptor 1/immunology
Humans
Hypersensitivity, Immediate/etiology
Ovarian Neoplasms/therapy
Receptors, IgE/immunology

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1111/j.1365-2222.2011.03764.x

Cite this

@article{eee1cfaea0754993ab9cfa0a10296bd4,

title = "Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?",

keywords = "Animals, Antibodies, Monoclonal, Murine-Derived/adverse effects, Basophils/immunology, Carcinoma/therapy, Female, Folate Receptor 1/immunology, Humans, Hypersensitivity, Immediate/etiology, Ovarian Neoplasms/therapy, Receptors, IgE/immunology",

author = "E. Jensen-Jarolim and J. Singer",

year = "2011",

month = oct,

doi = "10.1111/j.1365-2222.2011.03764.x",

language = "English",

volume = "41",

pages = "1337--1340",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",